SBP GROUP (01177.HK): TQC3721 Phase III completes enrolment

NewTimeSpace News: On 8 October 2026, Sino Biopharmaceutical Limited (01177.HK) announced that the pivotal Phase III registration trial (PACER-III) of TQC3721 inhalation suspension for maintenance treatment of chronic obstructive pulmonary disease (COPD) has completed full enrolment. The Class 1 innovative drug is developed by its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

TQC3721 is a dual PDE3/4 inhibitor. PDE3 is highly expressed in airway smooth muscle and PDE4 in inflammatory cells, so the drug relaxes airway smooth muscle to improve ventilation and inhibits inflammation to control disease progression. Available as a nebulized suspension and a dry powder inhaler, the former showed best-in-class potential in Phase II and has completed Phase III enrolment, while the latter has advanced to Phase II. It may become China's first approved domestic inhaled dual PDE3/4 inhibitor.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.